LAUSR

The results of this study are consistent with the results of a single study published in Radiology earlier this year by Wolfson et al, which analyzed 1217 patients who received the COVID-19 vaccination and had breast imaging. That study was notable because it contained long-term follow-up data that demonstrated persistent lymphadenopathy in patients up to 43 weeks after COVID-19 vaccination Wolfson and colleagues also found that 537 (44%) of the 1217 patients that received the COVID-19 vaccination had axillary lymphadenopathy identified on either mammography or breast US. Both studies did not find a single malignancy in asymptomatic patients with neither a concurrent suspicious mammographic finding nor a recent breast cancer diagnosis. Therefore, the high incidence of adenopathy in both studies and the persistence of the adenopathy suggest that follow-up imaging examinations may be unnecessary.